Bank of New York Mellon Corp increased its stake in VolitionRx Limited (NYSEAMERICAN:VNRX) by 11.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 85,925 shares of the medical research company’s stock after acquiring an additional 8,817 shares during the quarter. Bank of New York Mellon Corp’s holdings in VolitionRx were worth $334,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of VolitionRx by 5.5% in the fourth quarter. BlackRock Inc. now owns 1,872,643 shares of the medical research company’s stock worth $7,285,000 after buying an additional 97,375 shares during the last quarter. Morgan Stanley increased its stake in VolitionRx by 11.0% during the third quarter. Morgan Stanley now owns 344,563 shares of the medical research company’s stock valued at $1,106,000 after purchasing an additional 34,197 shares during the last quarter. State Street Corp increased its stake in VolitionRx by 9.9% during the third quarter. State Street Corp now owns 259,032 shares of the medical research company’s stock valued at $831,000 after purchasing an additional 23,371 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in VolitionRx by 2.4% during the fourth quarter. GSA Capital Partners LLP now owns 115,935 shares of the medical research company’s stock valued at $451,000 after purchasing an additional 2,684 shares during the last quarter. Institutional investors and hedge funds own 14.19% of the company’s stock.
In other VolitionRx news, insider Jason Bradley Md Terrell sold 10,000 shares of the company’s stock in a transaction dated Friday, February 5th. The shares were sold at an average price of $5.37, for a total value of $53,700.00. Following the completion of the sale, the insider now directly owns 34,949 shares of the company’s stock, valued at approximately $187,676.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 19.60% of the company’s stock.
VolitionRx (NYSEAMERICAN:VNRX) last posted its quarterly earnings data on Sunday, March 21st. The medical research company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities analysts expect that VolitionRx Limited will post -0.44 EPS for the current fiscal year.
Several analysts have weighed in on the stock. Aegis boosted their target price on shares of VolitionRx from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, January 25th. Cantor Fitzgerald assumed coverage on shares of VolitionRx in a research note on Monday, March 15th. They set an “overweight” rating and a $8.00 target price for the company.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.
Recommended Story: Why Invest in Dividend Kings
Want to see what other hedge funds are holding VNRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VolitionRx Limited (NYSEAMERICAN:VNRX).
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.